{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:47:28Z","timestamp":1768427248004,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5428,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.nurt.2008.08.011","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T15:11:21Z","timestamp":1223133081000},"page":"535-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Current and Future Standards in Treatment of Myasthenia Gravis"],"prefix":"10.1016","volume":"5","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Schneider-Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.08.011_bib1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2008.08.011_bib2","series-title":"Myasthenia gravis and myasthenic syndromes","first-page":"87","article-title":"The immunopathogenesis of myasthenia gravis","author":"Hohlfeld","year":"1999"},{"key":"10.1016\/j.nurt.2008.08.011_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib4","series-title":"Neurological disorders: course and treatment","first-page":"1341","article-title":"Therapy of myasthenia gravis and myasthenic syndromes","author":"Hohlfeld","year":"2003"},{"key":"10.1016\/j.nurt.2008.08.011_bib5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(77)92118-3","article-title":"Intrathymic pathogenesis and dual genetic control of myasthenia gravis","volume":"1","author":"Wekerle","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.08.011_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02889966","article-title":"Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis","volume":"52","author":"Kirchner","year":"1986","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.nurt.2008.08.011_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.nurt.2008.08.011_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Strobel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nurt.2008.08.011_bib10","first-page":"A420","article-title":"Myasthenia gravis: pathogenesis and immunotherapy","volume":"104","author":"Schneider-Gold","year":"2007","journal-title":"Dtsch \u00c4rzteblatt"},{"key":"10.1016\/j.nurt.2008.08.011_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00001622-200009000-00007","article-title":"Thymoma","volume":"12","author":"Muller-Hermelink","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.nurt.2008.08.011_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nurt.2008.08.011_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review)-Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.011_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nurt.2008.08.011_bib16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.011_bib17","series-title":"Immuntherapie neurologischer Erkrankungen","author":"Gold","year":"2006"},{"key":"10.1016\/j.nurt.2008.08.011_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.20543","article-title":"Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases","volume":"34","author":"Schneider-Gold","year":"2006","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.nurt.2008.08.011_bib20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/01.wnl.0000324254.97372.e0","article-title":"The muddle of mycophenolate mofetil in myasthenia","volume":"71","author":"Benatar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.011_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"Schneider","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.011_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin-a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis-a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.011_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.63.8.1066","article-title":"Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.1996.sp021293","article-title":"Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor","volume":"492","author":"Bufler","year":"1996","journal-title":"J Physiol (Lond)"},{"key":"10.1016\/j.nurt.2008.08.011_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1749-6632.1987.tb51406.x","article-title":"Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels","volume":"505","author":"Heininger","year":"1987","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl","key":"10.1016\/j.nurt.2008.08.011_bib30","first-page":"43","article-title":"Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide","volume":"19","author":"Flachenecker","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.nurt.2008.08.011_bib31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2008.08.011_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.nurt.2008.08.011_bib33","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00415-007-0593-9","article-title":"Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease","volume":"254","author":"Chan","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.08.011_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of musk antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle & Nerve"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.08.011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:37:38Z","timestamp":1761806258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1878747923004658"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.011","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Future Standards in Treatment of Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}